CT102

CT102 is the code name for at least two distinct investigational drugs in development: 1. **Antisense Oligonucleotide Targeting IGF-1R** - This version of CT102 is an antisense oligonucleotide (ASO) designed to target insulin-like growth factor 1 receptor (IGF-1R) mRNA, thereby inhibiting its expression and inducing apoptosis in cancer cells. It has been studied primarily for hepatocellular carcinoma and other liver cancers. Preclinical and phase I studies have shown that it is safe and tolerable in patients with advanced liver cancer, with ongoing phase II trials in China[1][6]. The drug works by gene therapy technology using ASOs to downregulate IGF-1R expression as a targeted therapy[6]. 2. **Histone Deacetylase (HDAC) Inhibitor** - Another drug named CT-102 is a proprietary histone deacetylase inhibitor developed by Cetya Therapeutics. It has demonstrated potent activity against EGFR-mutant and KRAS-mutant lung cancer cell lines as well as other difficult-to-treat solid tumors[5]. This HDAC inhibitor alters gene expression related to oncogenic pathways such as Check 1 and Wnt inhibitors, showing nanomolar activity against various resistant tumor subtypes[5]. 3. **Platelet-Derived Wound Healing Formula** - A third unrelated product called "CT 102" or "PDWHF" refers to a topical mixture of naturally occurring growth factors derived from platelets used experimentally for wound healing, particularly diabetic foot ulcers[3][8]. This formulation contains multiple growth factors including PDGF, EGF, TGF-beta among others. This entry focuses on the first two pharmaceutical candidates relevant to oncology.